TY - JOUR
T1 - Thrombotic recurrences and bleeding events in APS vascular patients
T2 - A review from the literature and a comparison with the APS piedmont cohort
AU - The Piedmont APS Consortium
AU - Bazzan, M.
AU - Vaccarino, A.
AU - Stella, S.
AU - Bertero, M. T.
AU - Carignola, R.
AU - Montaruli, B.
AU - Roccatello, D.
AU - Shoenfeld, Y.
AU - Osvaldo, Giachino
AU - Fabio, Marletto
AU - Simone, Baldovino
AU - Luisa, Sosso
AU - Luca, Marozio
AU - Valeria, Data
AU - Giuseppe, Guida
AU - Patrizia, Bigo
AU - Cristiana, Rollino
AU - Michela, Ferro
AU - Loredana, Colla
AU - Eirini, Karvela
AU - Raffaele, Pellerito
AU - Emanuela, Bellis
AU - Aldo, Maina
AU - Valentina, Donvito
AU - Barbara, Nicolino
AU - Piercarla, Schinco
AU - Piera, Sivera
AU - Anna, Kuzenko
AU - Emanuela, Napolitano
AU - Domenico, Cosseddu
AU - Cristiana, Marchese
AU - Nicoletta, Romeo
AU - Giulia, Seminara
AU - Maria, Stefanidou Erato
AU - Filippo, Molinari
AU - Laura, Contino
AU - Roberto, Santi
AU - Gabriella, Nallino Maria
AU - Roberta, Calvi
AU - Piero, Stratta
AU - Agata, Bizzocchi
AU - Flavio, Bobbio
AU - Sainaghi, Pier Paolo
AU - Daniele, Sola
N1 - Publisher Copyright:
© 2012 Elsevier B.V. All rights reserved.
PY - 2013
Y1 - 2013
N2 - In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studieswere selected and evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR range 3-4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed.
AB - In APS vascular patients, thrombotic recurrences are more frequent than in non-APS thrombotic patients. To better define this clinical setting, a systematic review of the literature after 1999 was performed: 8 cohort studies (including the recent APS Piedmont Cohort) and 6 intervention studieswere selected and evaluated. Thrombotic recurrences, bleeding events, therapeutic strategies, antiphospholipid (aPL) profile, inherited and acquired risk factors (when present) were calculated and compared. Emerging risk factors for thrombotic recurrences include withdrawal of oral anticoagulant therapy (OAT), high intensity OAT (INR range 3-4), aPL profile (triple positivity, Miyakis types 1 and 2a profiles) and association with inherited or acquired pro-thrombotic risk factors. Moreover, there are evidences that high risk (mainly for aPL profile) APS vascular patients have a high recurrence rate in spite of correct OAT treatment. Clinical trials in this clinical setting are needed.
KW - Antiphospholipid syndrome
KW - Thrombosis
KW - Thrombotic recurrences
UR - https://www.scopus.com/pages/publications/85027473271
U2 - 10.1016/j.autrev.2012.11.007
DO - 10.1016/j.autrev.2012.11.007
M3 - Review article
SN - 1568-9972
VL - 12
SP - 826
EP - 831
JO - Autoimmunity Reviews
JF - Autoimmunity Reviews
IS - 8
ER -